Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P230009/S021

Shield

Guardant Health, Inc. · Decision date Oct 5, 2026

FDA DECISIONP230009/S021

What did the FDA decide?

FDA records P230009/S021 as a supplement to PMA P230009, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Oct 5, 2026.

FDA approval order statement

approval of a secondary vendor
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Medical Genetics
Decision date
Oct 5, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P230009/S021
Regulatory pathway
PMA supplement
Product code
PHP
Decision code
OK30
Decision date
Oct 5, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: System, colorectal neoplasia, DNA methylation and hemoglobin detection.

Product code
PHP
FDA device class
3

For the original device and its historical approval scope, see PMA P230009. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P230009/S021 received

    Application receipt date recorded by FDA.

  2. P230009/S021 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P230009. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P230009

Product / regulatory recordCompanyPathwayDecision dateSource
ShieldP230009
Guardant Health, Inc.PMA approvalJul 26, 2024FDA
ShieldP230009/S020
Guardant Health, Inc.PMA supplementSep 16, 2026FDA

Explore the linked device profile

Other records with product code PHP

Product / regulatory recordCompanyPathwayDecision dateSource
SimpleScreen CRCP250029/S003
Freenome, LLCPMA supplementOct 27, 2026FDA
Freenome, LLCPMA approvalJul 24, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Guardant Health, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
3000 Hanover St., Palo Alto, CA, 94304

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records